USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: EVAS THERAPEUTICS, LLC.
Address: 613 HUNTLEY HEIGHTS DRIVE
BALLWIN, MO
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $320,133.00 2
SBIR Phase II $1,365,616.00 1

Award List:

Novel Recombinant Anticoagulant Proteins

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tzechein Wun
Award Amount: $152,652.00
Abstract:
DESCRIPTION (provided by applicant): Phase I: Clot formation in the blood vessel (thrombosis) causes a broad range of serious clinical conditions, such as unstable angina, acute myocardial infarction, ischemic stroke, deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation,… More

Pharmacologic treatment of thromboembolism

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tzechein Wun
Award Amount: $167,481.00
Abstract:
DESCRIPTION (provided by applicant): Thromboembolic disorders are major causes of morbidity and mortality in the Western societies. Anticoagulants are pivotal agents in the prevention and treatment of arterial and venous thrombosis. The limitations of curr ently approved anticoagulant drugs have… More

Novel antithrombotic agents to prevent hemodialysis vascular access failure

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Tze-chein Wun – 636-527-4545
Award Amount: $1,365,616.00
Abstract:
DESCRIPTION (provided by applicant): Currently, more than 60 % of end-stage renal diseases patients who require chronic hemodialysis are accessed through a native arteriovenous fistula (AVF) or synthetic graft (AVG). Unfortunately, primary failure rates were as high as 60 % at 6 months after AVF… More